Published in Int J Mol Sci on March 06, 2015
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
The specificities of protein kinase inhibitors: an update. Biochem J (2003) 7.76
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 6.41
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta (2000) 2.46
Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog Nucleic Acid Res Mol Biol (1999) 1.97
A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. J Med Chem (1964) 1.62
Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci (2009) 1.44
y-Randomization and its variants in QSPR/QSAR. J Chem Inf Model (2007) 1.33
The role of DYRK1A in neurodegenerative diseases. FEBS J (2010) 1.23
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun (2010) 1.14
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem (2012) 1.04
Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. Structure (2013) 1.03
Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J (2009) 1.02
Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci (1998) 1.00
Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. J Med Chem (2011) 0.95
Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr Protein Pept Sci (2008) 0.94
Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem (2008) 0.94
Heuristic molecular lipophilicity potential (HMLP): a 2D-QSAR study to LADH of molecular family pyrazole and derivatives. J Comput Chem (2005) 0.92
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem Neurosci (2012) 0.91
Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR). J Comput Chem (2008) 0.91
Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles. Chem Commun (Camb) (2009) 0.89
Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. J Comput Chem (2009) 0.89
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett (2011) 0.89
Investigation into adamantane-based M2 inhibitors with FB-QSAR. Med Chem (2009) 0.88
Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg Med Chem (2008) 0.87
(Q)SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther (2012) 0.87
Putative therapeutic agents for the learning and memory deficits of people with Down syndrome. Bioorg Med Chem Lett (2006) 0.84
Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A. Cell Mol Life Sci (2011) 0.81
Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg Med Chem Lett (2013) 0.79
Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. J Chem Inf Model (2013) 0.79
Two new peltogynoids from Acacia nilotica Delile with kinase inhibitory activity. Planta Med (2009) 0.78
Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. Eur J Med Chem (2012) 0.78